NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) Short Interest Down 17.3% in June

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) was the target of a large drop in short interest in June. As of June 15th, there was short interest totalling 8,100 shares, a drop of 17.3% from the May 31st total of 9,800 shares. Based on an average daily volume of 124,900 shares, the short-interest ratio is presently 0.1 days. Approximately 0.1% of the company’s stock are sold short.

NeuroSense Therapeutics Stock Up 14.8 %

Shares of NeuroSense Therapeutics stock traded up $0.16 on Tuesday, reaching $1.24. The company’s stock had a trading volume of 2,500,784 shares, compared to its average volume of 242,171. The company has a market capitalization of $16.95 million, a price-to-earnings ratio of -1.41 and a beta of 1.52. The firm’s fifty day simple moving average is $1.13 and its two-hundred day simple moving average is $1.26. NeuroSense Therapeutics has a 52 week low of $0.40 and a 52 week high of $2.33.

NeuroSense Therapeutics (NASDAQ:NRSN) last issued its quarterly earnings data on Friday, April 5th. The company reported ($0.16) EPS for the quarter.

About NeuroSense Therapeutics

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.